A Clinical Trial of Plasmakinetic Transurethral Enucleation and Resection of the Prostate in Patients with Benign Prostatic Hyperplasia more than 80 g

A Clinical Trial of Plasmakinetic Transurethral Enucleation and Resection of the Prostate in Patients with Benign Prostatic Hyperplasia more than 80 g

We evaluated the efficacy and safety of plasmakinetic transurethral enucleation and resection (TUERP) for benign prostatic hyperplasia (BPH) more than 80g. From January 2011 to December 2013, 37 patients with BPH larger than 80 g who un-derwent plasmakinetic TUERP were retrospectively assessed. The postoperative outcomes such as operative time, resected adenoma weight, resection rate, catheterization time, postoperative hospital stay and complications were reviewed. Patients were followed up at 1, 3, 6 months postoperatively. The mean prostate volume was 108.7 ± 21.7 g (range, 80 to 200 g), The mean resection chip weight was 53.5 ± 15.7 g (range, 29 to 101 g), The mean resection ratio was 82.0 ± 12.9%. Catheteriza-tion time and hospital stay was 2.4 ± 1.6 days and 3.4 ± 1.6 days respectively. Perioperative loss of hemoglobin and serum sodium was 1.5 ± 0.8 g/dL and 2.3 ±2.0 mmol/L respectively. International Prostate Symptom Score (IPSS), quality of life (QOL) score, maximum flow rate (Qmax), post void residual urine volume (PVR) were significantly improved at all fol-lowup intervals compared with baseline. No major complication including TUR syndrome was developed. Plasmakinetic TUERP is considered a safe, effective and technically feasible procedure for the large volume BPH more than 80 g at short-term followup.